You are here

  • Home
  • Online First
  • Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by Kaklamanos et al

Article Text

Article menu

other Versions

Download PDFPDF
Correspondence response
Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by Kaklamanos et al
  1. Sofia Ramiro1,2,
  2. Rémy L M Mostard3,
  3. Robert B M Landewé1,4
  1. 1Rheumatology, Zuyderland Medical Center, Heerlen, The Netherlands
  2. 2Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
  3. 3Department of Pulmonology, Zuyderland Medical Centre Heerlen, Heerlen, The Netherlands
  4. 4Amsterdam Rheumatology Center, AMC, Amsterdam, The Netherlands
  1. Correspondence to Dr Sofia Ramiro, Department of Rheumatology, Zuyderland Medical Center, 6419 PC Heerlen, Limburg, The Netherlands; sofiaramiro{at}gmail.com

https://doi.org/10.1136/annrheumdis-2021-220474

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We have read with interest the letter by Kaklamanos et al1 pertaining to our COVID-19 High-intensity Immunosuppression in Cytokine storm syndrome (CHIC) study.2 Kaklamanos et al share their positive experience with tocilizumab administered to three patients with severe COVID-19 pneumonia, accompanied by signs of hyperinflammation, as described in our …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors SR drafted the response. All authors reviewed and approved the final response.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles